Mayne Pharma's branded products revenue of $61.9 million...

Mayne Pharma's branded products revenue of $61.9 million represented an impressive 484% lift on FY22.Portfolio products revenue of $57 million was down 38% on FY22. International revenue increased 19% to $64.7 million, largely due to increased contract manufacturing in 2H FY23.A primary focus in FY23 was transforming Mayne Pharma into a specialty pharmaceutical company. It wants to attain a leading position in women's health and dermatology and return to profitability.A number of milestones occurred during FY23.In August 2022, Mayne Pharma announced the sale of its Metrics Contract Services business for US$475 million.In October, the company announced a fully franked special dividend of 2.72 cents per share. It also announced a pro-rata return of capital of 3.8 cents per share, but this was cancelled in February.Investors thought this was a smart decision, with the Mayne Pharma share price lifting 5.4% on the news.In December, Maybe Pharma acquired the exclusive US license to a portfolio of on-market women's health products (ANNOVERA, IMVEXXY and BIJUVA) and pre-natal vitamins. The deal cost US$140 million and included potential sales-based milestone cash payments and sales-based royalties.